Molecular characterization of breast cancer in young Brazilian women;Caracterização molecular do câncer de mama em mulheres brasileiras jovens

Revista da Associacao Medica Brasileira

Volumn 56, Issue 3, 2010, Pages 278-287

  de Carvalho, Leda Viegas ^a   Pereira, Emílio Marcelo ^b   Frappart, Lucien ^c   Boniol, Mathieu ^d   Bernardo, Wanderley Marques ^a   Tarricone, Vicente ^a   Tavtigian, Sean ^d   Southey, Melissa Caroline ^e  

^a Seção de Anatomia Patológica Hospital Guilherme Álvaro   (Brazil)

^b Responsável pelo Serviço de Anatomia Patologica do Laboratorio Salomao and Zoppi   (Brazil)

^c EDOUARD HERRIOT HOSPITAL   (France)

^d INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Breast neoplasms; Genes, BRCA1; Immunohistochemistry; Loss of heterozygosity; Microsatellite instability

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ADULT; ARTICLE; BASAL CELL CARCINOMA; BLOOD; BRAZIL; BREAST TUMOR; CHI SQUARE DISTRIBUTION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOSITY LOSS; HUMAN; MICROSATELLITE INSTABILITY; PAGET NIPPLE DISEASE; TUMOR SUPPRESSOR GENE;

ADULT; BRAZIL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHI-SQUARE DISTRIBUTION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; HUMANS; LOSS OF HETEROZYGOSITY; MICROSATELLITE INSTABILITY; NEOPLASMS, BASAL CELL; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77955335830     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, et al. (2000). Molecular portraits of human breast tumours. Nature 406:747-752
2. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen M, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, et al. (2001).Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874.
3. vant Veer LJ, Dai H, van de Vijver MJ, He DY, Hart AMA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536
4. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, et al. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418-8423
5. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jzaeri A, Martiat P, Fox SB, Harris AL, Liu ET. (2003). Breast cancer classification and prognosis based on gene expression profiles from a populationbased study. Proc Natl Acad Sci USA 100:10393-10398
6. van de Rijn M. Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, Torhorst J, Sauter G, Zuber M, Kochli OR, Mross F, Dieterich H, et al. (2002). Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 161:1991-1996
7. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. (2004). Immunohistochemical and clinical charecterization of the basal-like subtype of invasive breast carcinoma. Clinical Cancer Res 10: 5367-5374
8. Matos I, Dufloth R, Alvarenga M, Zeferino LC, Schmitt F. (2005). p63, cytoker-atin5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchow Arch DOI 10.1007/s00428-005-0010-7
9. El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JFR, Macmillian D, Mlamey RW, Ellis IO (2005). High-throughput protein expression analysis using microarray technology of a large well-characterized series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analysis. Int J Cancer 116: 340-350
10. Rakha E A, Reis-Filho J, Ellis IO (2008). Basal-like Breast Cancer: a critical review. J Clin Oncol 26: 2568-2581
11. Diaz LK, Cryns VL, Symmans WF, Sneige N. (2007). Triple negative breast carcinoma and basal phenotype: from expression profiling to clinical practice. Adv Anat Pathol 14: 419-430
12. Gusterson B A, Ross DT, Heath VJ, Stein T (2005). Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Research 7 (4): 143-148.
13. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA. (2003). Germline BRCA1 mutations and basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482-1485
14. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon Y, Claude JC, Hamann U, et al. (2005). Prediction of BRCA1 stauts in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11: 5175-5180
15. Arnes JB, Brunet J, Stefansson IM, Bégin LR, Wong N, Chappuis O, Akslen LA, Foulkes WD. (2005). Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 11(11): 4003-4011
16. Dubsky PC, Gnant M F, Taucher S, Roka S, Kandioler D, Pichler-Gebhard B, Agnster I, et al. (2002). Young age is an idependent adverse prognostic factor in premenopausal patients with breast cancer. Clinical Breast Cancer 3: 65-72
17. Janatova M, Zikan M, Dundr P, Matous B, Pohlriech P. (2005). Novel somatic mutation in the BRCA1 gene in sporadic breast tumours. Human Mutation DOI: 10.1002/humu.9308
18. Knudson AG, Jr (1971). Mutation and Cancer: statistical study of retinobalstoma. Proc. Natl Acad Sci USA 68: 820-823
19. Kollias J, Man S, Marafie M, Carpenter K, Pinder S, Ellis IO, Blamey RW, Cross G, Brook JD (2000). Loss of heterozygosity in bilateral breast cancer. Breast Cancer Res and Treat 64: 241-251
20. Querzoli P, Albonico G, di Iasio MG, Ferretti S, Rinaldi R, Cariello A, Pedriali M, Matteuzzi M, Maestri I, Nenci I. (2001). Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in Young women. Breast Cancer Res and Treat 66: 135-142
21. Santos SC, Cavalli LR, Cavalli IJ, Lima RS, Haddad BR, Ribeiro EMSF. (2004). Loss of heterozygosity of BRCA1 and FHIT genes in patients with sporadic breast cancer from Southern Brazil. J Clin Pathol 57: 374-77
22. nd edn. Churchill Livingstone, New York
23. Martins SJ, Yamamoto CA (2008). Clinical and economic issues in adjuvant chemotherapy for HER-2 positive breast cancer. Rev Assoc Med Bras. 54(6):494-9
24. Rocha RM, Nunes CB, Sanches FS, Rocha GF, Oliveira FN, Reis-Filho JS, Lambrs MB, Gobbi H (2009). Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer._Rev Assoc Med Bras.55(2):163-8
25. Th Annual Meeting of USCAP Atlanta, Georgia, 11-17 February
26. Armes JE, Trute L, White D, Southey MC, Hammet F, Tesoriero A, Hutchins AM, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ. (1999). Distinct molecular pathogenesis of early-onset breast cancer in BRCA1 and BRCA2 mutation carriers: A population-based Study. Cancer Research 59: 2011-2017
27. Eerola H, Heikkila P, Tamminen A, Aittomaki K, Blomqvist C, Nevanlinna H. (2005). Relationship of patients' age to histopathological features of breast tumours in BRCA1 and BRCA2 and mutation negative breast cancer families. Breast Cancer Research DOI 10.1186/bcr1025
28. Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR, Easton DF, Venter DJ (1999). Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev; 8:741-7.
29. Southey MC, Tesoriero AA, Andersen CR, Jennings KM, Brown SM, Dite GS, Jenkins MA, Osborne RH, Maskiell JA, Porter L, Giles GG, McCredie MR, Hopper JL, Venter DJ. (1999) BRCA1 mutations and other sequence variants in a population-based sample of Australian women with breast cancer. Br J Cancer;79:34-9.
30. Watson P, Lynch HT (1993) Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 71:677-85
31. Aarnio M, Mcklin JP, Aaltonen LA, Nystrom-Lahti M, Jarvinen HJ.(1995) Lifetime risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 64:430-433
32. Southey MC, Young MA, Whitty J Mifsud S, Keilar M, Mead L, Trute L, Aittomaki K, McLachlan SA, Debinski H, Venter DJ, Armes JE. (2001) Molecular Pathologic analysis enhances the diagnosis and management of Muir-Torre syndrome and gives insight into its underlying molecular pathogenesis. Am J Surg Path 25:936-941
33. Risinger JI, Barrett JC, Watson P, Lynch HT, Boyd J. (1996) Molecular genetic evidence of the occurrence of breast cancer as an integral tumour in patients with the hereditary non-polyposis colorectal carcinoma syndrome. Cancer 77:1836-1843
34. Southey MC, Jenkins MA, Mead L, Whitty J, Trivett M, Tesoriero AA, Smith LD, Jennings K, Grubb G, Royce SG, Walsh MD, Barker MA, Young JP, Jass JR, St John DJ, Macrae FA, Giles GG, Hopper JL. (2005) Mismatch repair genemutation testing, immunohistochemistry and microsatellite instability testing in a population-based series of unselected early-onset colorectal cancers. J Clin Oncol 23:6524-6532
35. Poweierska-Czarny J, Miscicka-Sliwka D, Czarny J, Grzybowski T, Wozniak M, Drewa G, Czechowicz W, Sir J (2003). Analysis of microsatellite instability and loss of heterozygosity in breast cancer with the use of a well characterized multiplex system. Acta Biochimica Polonica 50: 1195-1203
36. Adem C, Soderberg CL, Cunningham JM, Reynolds C, Sebo TJ, Thibodeau SN, Hartmann LC, Jenkins RB. (2003). Microsatellite instability in hereditary and sporadic breast cancers. Int J Cancer 107:580-582
37. Cui J, Shen F, Jiang F, Wang Y, Bian J, Shen Z.(1998). Loss of heterozygosity and microsatellite instability in the region including BRCA1 of breast cancer in Chinese. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 15: 348-30
38. Chen XR, Zhang WZ, Lin XQ, Wang JW.(2006).Genetic instability of BRCA 1 gene at locus D17S855 is related to clinicopathological behaviors of gastric cancer from Chinese population. World J Gastroenterol 12: 4246-9